



The genetic architecture of sporadic and multiple consecutive miscarriage 





Description of participating cohorts 
UKBB 
The UK Biobank (UKBB) is a prospective cohort of 502,637 (~5% of the >9.2 million 
invited) people aged 37-73 recruited in 2006-2010 from across the UK, who completed detailed 
questionnaires regarding socio-demographic and lifestyle characteristics and their medical 
history, and had a clinical assessment. Additional information about medical conditions (both 
existing at baseline and occurring during follow-up) has been obtained through linking with 
hospital admission and mortality data. Full details of the study have been reported elsewhere 1. 
Ethics approval for the UKBB was provided by the UK National Health Service (NHS) Research 
Ethics Service (11/NW/0382) and all participants provided informed written consent. 
Information on miscarriages was retrieved from touchscreen questionnaire field 3839 “How 
many spontaneous miscarriages?”, which is collected from participants who indicated they had 
had a stillbirth, spontaneous miscarriage or termination, as defined by their answers to data field 
2774 “Have you ever had any stillbirths, spontaneous miscarriages or terminations?”. We 
additionally used data from hospital in-patient episode data fields 41202 and 41204 (“Diagnoses 
– main ICD10” and “Diagnoses – secondary ICD10”, diagnosis codes O02.1 and O03, and N96). 
In the UKBB, most of the data has been collected during the initial assessment visit, however, 
for some participants, data have been additionally collected on repeat assessment visits. 
Therefore, if a participant has answered the same question on multiple occasions, answers were 
aggregated, excluding participants who have given discordant answers on different occasions. 
Participants giving no answer to relevant questions, or answering “Prefer not to answer” or “Do 
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not remember” were excluded from the analysis. Analyses were performed under data 
applications 17805 (“Dissemination of shared genetics across phenotypes associated with 
reproductive health and related endophenotypes”), 11867 (“Dissection of the Genetic 
Susceptibility of Obesity Traits and their Comorbidities”), and 16729 (“MR-PheWAS: 
hypothesis prioritization among potential causal effects of body mass index on many outcomes, 
using Mendelian randomization”). The GWAS analysis included 37,150 women of White 
European ancestry with self-reported or electronic health record-derived sporadic miscarriage, 
421 with multiple consecutive miscarriage and 164,775 female controls (no miscarriages and no 
exclusion diagnoses) with available genome-wide data. The sporadic miscarriage trans-ethnic 
meta-analysis also included 511 cases and 1,424 controls of UK South-Asian ancestry, 390 cases 
and 957 controls of UK Caribbean ancestry, 132 cases and 433 controls of UK Chinese ancestry, 
and 273 cases and 482 controls of UK African ancestry. 
 
EGCUT 
The Estonian Genome Center of the University of Tartu (EGCUT; http://www.biobank.ee) 
is a population-based biobank with a total cohort size of 51,515 participants (aged 18-85+)2. The 
EGCUT cohort included a total of 3,368 women of White European ancestry with sporadic 
miscarriage, 113 with multiple consecutive miscarriage, and 17,996 women as controls. 
Information on miscarriages was retrieved from questionnaire fields “How many times have you 
got pregnant?” and “How many of the pregnancies ended with unintentional miscarriage?”, and 
based on ICD codes obtained from linking with Health Insurance Fund databases. The study was 
approved by the Ethics Review Committee of the University of Tartu (234T-12). All biobank 




The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective 
pregnancy/birth cohort that recruited 14,541 pregnancies of women resident in Avon, UK with 
expected dates of delivery 1st April 1991 to 31st December 1992. These women delivered 
14,062 live births and they, their partners and offspring have been followed-up since then with 
detailed repeat questionnaires, hands-on clinic assessments and record linkage. Full details of the 
study can be found elsewhere 3. ALSPAC is an accessible resource for the research community 
and the study website contains details of all the data that are available through a fully searchable 
data dictionary (http://www.bris. ac.uk/alspac/researchers/data-access/data-dictionary). Ethical 
approval for the ALSPAC was obtained from the ALSPAC Ethics and Law Committee and the 
UK National Health Service Research Ethics Committee (full details at 
http://www.bristol.ac.uk/alspac/researchers/data-access/ethics/lrec-approvals/#d.en.164120). 
Women provided written informed consent. 
At recruitment and follow-up, the women have been asked about miscarriage and stillbirth. 
For this study, we considered miscarriages reported at baseline regarding pregnancies before the 
index child, and at subsequent follow-ups regarding pregnancies after the index child. At 
baseline, women were asked “Have you ever had any miscarriages?” and “How many times have 
you miscarried?”. At the follow-up assessments, miscarriage was retrieved from information 
asked about: i. outcome of each pregnancy after the index child (i.e. “Since child’s <age at 
follow-up>’s birthday, have you become pregnant?”, “What happened in the 1st pregnancy?”, 
“What happened in the 2nd pregnancy?”), ii. occurrence of miscarriage (i.e. “Since the study 
child was <age at follow-up>, have you had a miscarriage?”), and iii. whether a dilation and 
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curettage (D&C) occurred due to miscarriage (i.e. “Have you had a D and C (scrape) in the last 2 
years?” “Was this because of miscarriage?”). In total, 1,473 women had sporadic miscarriage, 
216 had multiple consecutive miscarriage, and 4,475 women had no miscarriage.  
 
QIMR 
       The QIMR samples were drawn from two cohorts of adult twins and their relatives (parents, 
siblings, adult children and spouses) who have taken part in a wide range of studies of health and 
well-being via previous postal questionnaires and telephone interview studies (questionnaires 
and methods are summarized in Medland et al., 2008 4). As a result, this sample includes related 
individuals, 1,145 women reporting sporadic miscarriage and 5,136 women who did not report 
experiencing miscarriage as controls. The QIMR Endo samples were drawn from a cohort of 
women with a confirmed surgical diagnosis of endometriosis, and for whom detailed 
reproductive history data are available 5,6. This sample includes only unrelated individuals, 497 
women reporting sporadic miscarriage and 1,078 women who did not report miscarriage as 
controls. For both samples miscarriage information was drawn from questionnaire fields “Have 
you ever had a miscarriage?” and “Number of miscarriages?”. Ethics approval for studies 
involving these individuals was granted by the QIMR Human Research Ethics Committee. 
Informed consent was obtained from all participants. 
 
iPSYCH 
       The iPSYCH2012 (Lundbeck Foundation Initiative for Integrative Psychiatric Research) 
dataset represents a Danish case-control cohort (a total of 76,657 participants) for psychiatric 
disorders. The iPSYCH cohort included a total of 1,173 women with sporadic miscarriage and 
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4,821 women as controls (all of White European ancestry). Women were considered sporadic 
miscarriage cases if they had an inclusion code (O02.1 and/or O03) on one or two separate 
occasions in their medical record. At the same time, individuals with any of the exclusion 
diagnoses mentioned below were not included in the analysis. Controls were selected from 
women who had not had a miscarriage and were matched based on genotyping wave, four 
controls for each case. The iPSYCH GWAS data were generated based on dried blood spot 
samples obtained during routine neonatal screening and stored in the Danish Neonatal Screening 
Biobank. Parents are informed in writing about the neonatal screening and that the samples can 
later be used for research, pending approval from relevant authorities7. The study was conducted 
under the iPSYCH study ethics approval given by the Danish Research Ethics Committee and 
has also been approved by the Danish Data Protection Agency. 
 
Lifelines 
The Lifelines dataset included in this study represents a subset of samples with available 
genotype data from the Lifelines prospective population-based cohort 8,9, examining in a unique 
three-generation design the health and health-related behaviours of 167,729 persons living in the 
North of The Netherlands. It employs a broad range of investigative procedures in assessing the 
biomedical, socio-demographic, behavioural, physical and psychological factors which 
contribute to the health and disease of the general population, with a special focus on multi-
morbidity and complex genetics. The Lifelines dataset was accessed under data application 
OV17-0393. Self-reported information on miscarriages was extracted from questionnaire field 
“How many miscarriages (up to 16 week) have you had?”. The sample includes 1,676 sporadic 
miscarriage cases and 5,091 female controls. The Lifelines study has been approved by the 
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review board of the University Medical Center, Groningen, and adheres to the principles 
expressed in the Declaration of Helsinki. All study participants provided written informed 
consent. 
 
Partners HealthCare Biobank 
The Partners HealthCare Biobank is a biorepository of consented patient samples at Partners 
HealthCare (the parent organization of Massachusetts General Hospital and Brigham and 
Women’s Hospital). All patients who participate in the Partners Biobank are consented for their 
samples to be linked to their clinical information for researchers at Partners HealthCare to 
conduct research on human health (including genomics, epidemiology and outcomes research) 
for which institutional review board approval was obtained. For the analyses described in this 
paper, only European American patients were included due to sample size. Sporadic miscarriage 
cases were identified using ICD codes and the same inclusion and exclusion criteria described 
above, resulting in 58 cases and 289 controls for analysis. 
 
MoBa-HARVEST 
The Norwegian Mother and Child Cohort Study (MoBa) is a prospective population-based 
pregnancy cohort study conducted by the Norwegian Institute of Public Health. Participants were 
recruited from all over Norway from 1999-2008. The women consented to participation in 41% 
of the pregnancies. The cohort now includes 114 500 children, 95 200 mothers and 75 200 
fathers. Blood samples were obtained from both parents during pregnancy and from mothers and 
children (umbilical cord) at birth. The cohort is described in the following publications 10–12. In 
the current study, a subset (n=8,000) of the MoBa cohort (genotyping effort HARVEST, also 
 8 
known as Njolstad1) is included. Sporadic miscarriage cases were defined based on 
questionnaire-derived data, and controls were also restricted to have at least one previous 
delivery. The analysis included 1,653 sporadic miscarriage cases and 3,199 female controls.  
A signed informed consent was obtained from all study participants. The administrative 
board of the Norwegian Mother, Father, and Child Cohort Study led by the Norwegian Institute 
of Public Health approved the study protocol. The establishment of MoBa and initial data 
collection was based on a license from the Norwegian Data Protection Agency and approval 
from The Regional Committee for Medical Research Ethics. The MoBa cohort is currently 
regulated by the Norwegian Health Registry Act. This study was approved by the Regional 
Committee for Medical and Health Research Ethics from Norway (2015/ 2425). 
 
BGI Chinese millionome database Phase I 140K study 
The BGI cohort represents a dataset of 141,431 Chinese women generated for non-invasive 
prenatal testing (NIPT), for whom whole-genome low-pass sequencing data are available 13. The 
study was reviewed and approved by the Institutional Review Board of BGI (BGI-IRB17088) in 
strict compliance with regulations regarding ethical considerations and personal data protection. 
A signed informed consent was obtained from all study participants. A subset of 135,115 
participants who reported their pregnancy history were included in this study, resulting in 8,865 
sporadic miscarriage cases and 126,290 controls for analysis.  
 
China Kadoorie Biobank 
The China Kadoorie Biobank is a prospective population-based cohort of 512,891 adults 
aged 30-79 years recruited from 10 geographically defined regions during 2004-2008, with 
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collection of questionnaire data, physical measurements and blood samples 14. The current study 
included data for 57,622 women, from whom 5,038 sporadic miscarriage cases and 51,696 
controls who had ever been pregnant were extracted based on self-reported data on miscarriages. 
Ethical approval for China Kadoorie Biobank was obtained jointly from the University of 
Oxford, the Chinese Center for Disease Control and Prevention (CCDC), and the regional CCDC 
from the 10 study areas, and all participants provided written informed consent.  
 
Women’s Health Initiative  
The Women’s Health Initiative (WHI), sponsored by the National Heart, Lung, and Blood 
Institute (NHLBI), is a long-term national health study that focuses on strategies for preventing 
heart disease, breast and colorectal cancer, and osteoporosis in postmenopausal women. Our 
meta-analysis included data from several GWAS substudies from the WHI project: WHI HIPFX 
(mostly European ancestry case-control study for hip fracture; 273 sporadic miscarriage cases 
and 708 controls), WHI Gecco cyto (European ancestry case-control study by the Genetics and 
Epidemiology of Colorectal Cancer Consortium; 274 sporadic miscarriage cases and 609 
controls), WHI WHIMS (WHI Memory Study; 411 sporadic miscarriage European ancestry 
cases and 950 controls), WHI GARNET (Genomics and Randomized Trials Network cohort 
study; 954 sporadic miscarriage cases and 2,096 controls of European American ancestry), WHI 
SHARE (SNP Health Association Resource; 1,151 sporadic miscarriage cases and 2,195 controls 
of Hispanic American ancestry, and 2,919 sporadic miscarriage cases and 4,546 controls of 
African American ancestry). Cases were identified based on self-administered questionnaire data 
from variable phv00078626.v6.p3 (‘How many miscarriages or unspecified type of 
pregnancies’). 
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The human genetic analysis of the WHI cohorts reported in this study were reviewed and 
approved by the Institutional Review Board of Washington University in St. Louis, under 




Gene-based genome-wide association analysis was carried out with MAGMA 1.06 15 
(Multi-marker Analysis of GenoMic Annotation) with default settings implemented in FUMA 16. 
Briefly, variants located in the gene body were assigned to respective protein-coding genes 
(n=18,929; Ensembl build 85), and the resulting SNP P-values are combined into a gene test-
statistic using the SNP-wise mean model 15. To adjust for multiple testing, genome-wide 
significance level was set at 2.6×10-6, according to the number of tested genes. No genes passed 
the threshold of significance. 
 
Look-up in GWAS browsers 
In order to assess the potential genetic overlap between miscarriage phenotypes and other 
traits, we conducted a lookup in the publicly available GWAS catalogue (e91_r2018-02-06) 
(https://www.ebi.ac.uk/gwas/), and GWAS browsers Oxford BIG browser 
(http://big.stats.ox.ac.uk/) and GWASAtlas 17 (http://atlas.ctglab.nl/) for the miscarriage-
associated variants identified in any of our three GWAS meta-analyses. One of our variants 
associated with multiple consecutive miscarriage (chr 9: rs7859844 showed nominal association 
with ‘stomach or abdominal pain’ (P=4.9×10-6) and venous thromboembolic disease (P=5.8×10-
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6)17, ‘CD314-CD158a+ NK cell proportion’ (P=3.3×10-6) and CD32+ mDC (dendritic cell) 
subset proportion (P=8.7×10-6)18. 
 
Functional annotation with FUMA (v1.3.1) 
As the first step, independent significant SNPs in the GWAS meta-analysis summary 
statistics were identified based on their P-values (P<5×10-8) and independence from each other 
(r2<0.6 in the 1000G phase 3 reference) within a 1Mb window. Thereafter, lead SNPs were 
identified from independent significant SNPs, which are independent of each other (r2<0.1). 
SNPs that were in LD with the identified independent SNPs (r2≥0.6) within a 1Mb window, 
have a MAF of ≥1% and GWAS meta-analysis P-value of >0.05 were selected as candidate 
SNPs and taken forward for further annotation. 
FUMA annotates candidate SNPs in genomic risk loci based on functional consequences on 
genes using the Annotate Variation (ANNOVAR, 2017-07-17) 19, CADD (a continuous score 
showing how deleterious the SNP is to protein structure/function; scores >12.37 indicate 
potential pathogenicity) 20 and RegulomeDB 21 scores (ranging from 1 to 7, where lower score 
indicates greater evidence for having regulatory function), 15 chromatin states from the 
Roadmap Epigenomics Project 22,23, eQTL data (GTEx v6 and v7) 24, blood eQTL browser 25, 
BIOS QTL browser 26, BRAINEAC 27, MuTHER 28, xQTLServer 29, the CommonMind 
Consortium 30, and 3D chromatin interactions from HI-C experiments of 21 tissues/cell types 31. 
FUMA maps genes to candidate SNPs using positional mapping, which is based on ANNOVAR 
annotations and maximum distance between SNPs (default 10 kb) and genes, eQTL mapping and 
chromatin interaction mapping. Chromatin interaction mapping was performed with significant 
chromatin interactions (defined as FDR<1×10-6). The two ends of significant chromatin 
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interactions were defined as follows: region 1, a region overlapping with one of the candidate 
SNPs; and region 2, another end of the significant interaction, used to map to genes based on 




The nature of PheWAS is that they are hypothesis generating. Whilst the application of a 
stringent p-value threshold helps to minimise false positive results, any suggestive associations 
need replication in independent datasets and appropriate sensitivity analyses to explore whether 
the associations are likely to be causal or reflect horizontal pleiotropy. This approach is not able 
to determine conclusively the nature of any causal effect, thus outcomes that are statistically 
significantly related to the exposure of interest (here multiple consecutive miscarriage) might be 
confounded. In this specific example, the MR-PheWAS was undertaken in a study that is not 
independent of the GWAS sample that identified the multiple consecutive miscarriage hits (it is 
the largest study contributing to that GWAS) and there may be over-fitting of the data. 
Furthermore, with only four rare SNPs the use of MR-Egger to explore horizontal pleiotropy 
may be unreliable. Lastly, the proportion of variation in multiple consecutive miscarriage 
explained by the genetic risk score (between 0.02% to 0.6%) is low (McFadden’s adjusted 
R2=0.0006, Efron’s R2=0.0002, Pseudo R2=0.0062), suggesting that we might have weak 
instrument bias. Given these considerations and the fact that the three associations that reached 
significance below our predefined Bonferroni threshold did not seem plausible causes or 
consequences of multiple consecutive miscarriage we did not explore any of those further. We 
did look at other outcomes in the top 10 lowest P-values (i.e. the group that deviate from the QQ 
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plot; Supplementary Figure 2) to see if any were more plausible. Supplementary Table 10 lists 
the top 10 (lowest P-values) outcomes with per multiple consecutive miscarriage allele 
association (SD) and P-value. With one exception none of these are outcomes that have been 
shown in previously published, or our, multivariable regression analyses and do not seem 
biologically plausible. The one exception is a suggestive causal effect of multiple consecutive 
miscarriage on endometriosis of the uterus (P=5.9×10-5). 
 
Two-sample Mendelian randomization of endometriosis on multiple consecutive 
miscarriage 
We used a two-sample MR approach 32 to explore the possible causal effect of 
endometriosis on multiple consecutive miscarriage. We obtained summary association results for 
genetic instruments for endometriosis from a recent meta-analysis of 11 genome-wide 
association case-control data sets33. Summary associations between each instrument and multiple 
consecutive miscarriage were estimated using Firth regression in the three European ancestry 
studies of our GWAS and meta-analysed using METAL 34. From the 19 SNPs associated with 
endometriosis, 18 were present in at least two of our three studies. After harmonization of the 
summary data sets, we used inverse variance weighting (IVW) 35 and MR-Egger 36 to obtain a 
pooled estimate of the association between the SNPs for endometriosis and multiple consecutive 
miscarriage. There was no evidence of a causal association between endometriosis and multiple 
consecutive miscarriage (IVW OR 1.18, 95% CI 0.84, 1.65 and MR-Egger OR 0.96, 95% CI 
0.23, 4.02) (Supplementary Figure 9). 
 
Colocalization analyses of multiple consecutive miscarriage and expression/protein levels 
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Associations between SNPs and protein levels were obtained from the INTERVAL study, 
where 2,994 unique proteins (3,283 measured aptamers) had been investigated in up to 3,301 
participants of European origin 37. We extracted genotype-expression data from the GTEx 
project version 7, with cis-genotype-expression data available for 48 different tissues 38. The 
sample sizes in GTEx varied between 80-491 depending on tissue, and approximately 85% of 
donors were of European origin (denoted “White” by GTEx) 38. We excluded one SNP 
(rs144887114) for the transcripts TLE1 and RP11-154D17.1 in the terminal ileum expression 
dataset because of unlikely effect estimates (over a trillion). Lastly, we used data from a recent 
cis-eQTL study in placenta, including 40 samples of European ancestry 39. For the placental data, 
we matched the rsIDs to genome position using GRCh 37 and the biomaRt R package 40,41. We 
further matched genome position to rsIDs using the file “All_20180423.vcf.gz” available at 
ftp://ftp.ncbi.nih.gov/snp/organisms/human_9606_b151_GRCh37p13/VCF/ 42 for multiple 
consecutive miscarriage. In all datasets, we removed SNPs that were missing relevant data, 
duplicated by position, or indels. 
We constructed an LD-reference panel using a subset of the UK Biobank 1 and the imputed 
data for use in the GCTA analyses. Briefly, we extracted a random subsample of 27,625 
participants in the “White British ancestry” subset, after excluding individuals that had 
withdrawn consent, mismatch between self-reported and genetically inferred sex, sex-
chromosome aneuploidy, reported incompatible ancestries in different assessments, or that were 
related to other individuals in the UK Biobank to a third degree or higher, heterozygosity or 
missingness outliers, or not included in the autosome phasing or in the kinship calculations 43. 
Genotype dosages were converted to best-guess genotypes using a hard-call threshold of 0.1. We 
excluded SNPs with an imputation info score ≤0.3, minor allele frequency <0.01%, Hardy-
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Weinberg equilibrium exact test P<1×10-6, or genotype missing call rate >0.05. Analyses were 
done in plink versions 1.90b3 and 2.00a-20170724 44.  
To compute estimates conditioned on the top expression SNPs, we used GCTA version 
1.91.4 45,46. Information on effect allele frequency for GTEx were taken from the files 
“GTEx_V7_cis_eqtl_summary.tar.gz (hg19)” (downloadable at 
http://cnsgenomics.com/software/smr/#DataResource). We first selected the top SNP using 
GCTA (option --cojo-top-SNPs), and thereafter computed estimates conditioned on the top SNP 
(option --cojo-cond).  
 Colocalization analyses were performed using R versions 3.4.3 and 3.5.1 (https://www.r-
project.org/), the coloc R package 47 and the coloc.abf() function using two different region sizes: 
2 Mb (or all available SNPs depending on dataset), as well as 400 kb as a sensitivity analysis. In 
INTERVAL, we investigated all proteins consisting of a gene with a transcription start site 
within 5 Mb of a top miscarriage SNP, with the region sizes centered around this SNP (using 
GRCh 37 and the biomaRt R package 40,41 to extract genes, gene positions and transcription start 
sites). Since GTEx only included cis-associations for SNPs +/- 1 Mb of the transcription start 
site, we only investigated transcripts where the top miscarriage SNP had been analyzed and was 
within 800 kb of the transcription start site to have sufficient area around each lead SNP to 
determine colocalization. For the 2 Mb region we used the entire 2 Mb region available in GTEx, 
whereas we centered the region on the top miscarriage SNP for the smaller region size of 400 kb. 
The placental genotype data only included summary statistics +/- 100 kb of each gene. Only the 
miscarriage hit rs143445068 had a gene (NAV2) with genotype associations ≥200 kb on each 
side, which we took forward for colocalization analysis using both all available SNPs as well as 
a region size of 400 kb centered on the top miscarriage SNP. 
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We manually inspected LocusCompareR (http://www.locuscompare.com/) plots for all risk 
locus-gene/protein-tissue combinations where the top available miscarriage SNP was associated 
with the expression/protein levels at P<0.05. One such combination, the rs7859844 risk loci and 
RP11-154D17.1 expression in visceral adipose tissue, seemed to contain two independent 
expression quantitative trait loci, including the miscarriage risk loci, albeit not at GWAS-
significance threshold. As coloc assumes a maximum of one causal variant per locus 47, we 
reconducted the colocalization analyses for that analysis using expression statistics conditioned 
on the top expression variant in GTEx. 
We used the prior probabilities (p1 = 1×10-4, p2 = 1×10-4, p12 = 1×10-6) in coloc 47, with the 
minor allele frequencies from the miscarriage dataset. For INTERVAL and GTEx, we directly 
supplied effect estimates, standard errors, P-values and the standard deviation in the outcome. 
There were no effect estimates and standard errors for the miscarriage and placental expression 
datasets 39; we supplied P-values for these. We set the threshold for colocalization at a posterior 
probability for colocalization (PP4) >0.8, for strong colocalization at PP4>0.9, and with a 
threshold for suggestive evidence of PP4>0.5 47. However, no risk locus-gene/protein-tissue 
combinations had evidence for colocalization. 
 
Supplementary Notes 
Supplementary Note 1. Phenotype definition 
There is ongoing discussion in the field on how to define different miscarriage phenotypes and 
distinguish the more severe recurrent miscarriage cases from sporadic miscarriage. According to 
current (April 2020) ESHRE (European Society on Human Reproduction and Embryology) and 
ASRM (American Society for Reproductive Medicine) guidelines48, recurrent miscarriage 
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(diagnosed with the ICD-10 code N96) is defined as 2 or more spontaneous abortions. However, 
this has not always been the case, and the most recent set of ESHRE guidelines was published in 
November 2017. Before that, the recurrent pregnancy loss definition varied from two 
miscarriages (not necessarily consecutive) 49,50, to three or more consecutive pregnancy losses 
51,52. Of note, the ESHRE 2018 guidelines acknowledged that using two miscarriage as the 
definition of recurrent miscarriage was at least in part to facilitate research, improve shared 
decision making with patients and provide them psychological support, rather than because of 
more specific evidence that this defined a unique phenotype. In fact, the ESHRE guidelines 
acknowledge not all guideline group members agreed with this definition demonstrating the 
continuing uncertainty in the field regarding the definition of recurrent miscarriage. Data support 
increasing numbers of previous miscarriages as being a risk factor for further miscarriage53 and 
increasing likelihood of aneuploid miscarriage54. 
All the multiple consecutive miscarriage cohorts (UKBB, EGCUT, ALPSAC) included in 
this study are from Europe and have received the N96 diagnosis before the updated ESHRE 
statement in 2017/ 2018 (majority of analyses were conducted in 2017-2018), therefore we  
combined the N96 diagnosis code with self-reported data for multiple consecutive miscarriage. 
For all of the reported associated loci (both for sporadic and multiple consecutive miscarriage), 
we do not see significant heterogeneity across cohorts, i.e. depending on the data used for 
phenotype definition. Therefore, we believe that at least for the reported associations, the results 
are not impacted by combining self-reported and electronic health record-derived cases. 
To further assess which would be the most appropriate cut-off for defining the sporadic 
miscarriage phenotype, we used the UKBB data (which is the largest contributing cohort) to 
evaluate the effect of having a different number of miscarriages on fertility (in this context 
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measured a) number of pregnancies and b) as the number of children (Supplementary Figure 1). 
Due to the definitions used to extract cases with 3 or more consecutive miscarriages from self-
reported data, this group has less children compared to the other groups and thus represents a 
miscarriage subphenotype with a more severe effect on fertility, compared to the group with 3 or 
more miscarriages that are not necessarily consecutive. Similarly, groups with one or two 
miscarriages are relatively similar in terms of distribution of number of children. 
 
We used the UKBB dataset also to explore the associations between the four identified 
signals and different miscarriage phenotypes (“1 miscarriage”, “2 miscarriages”, “3 or more 
miscarriages”, “3 or more consecutive miscarriages (multiple consecutive miscarriage)” (Table 
S16). rs146350366 identified in sporadic miscarriage analysis was nominally significant in both 
the “1 miscarriage” (P= 9.2×10-5) and “2 miscarriages” (P=0.017) analyses, but were 
statistically not significant (and had opposite effect direction) in the 3 or more miscarriage 
analyses. Two (rs7859844, rs183453668) of the three signals from multiple consecutive 
miscarriage analyses were nominally significant also in the “3 or more miscarriages” analyses 
(P=0.01 and P=0.04, respectively), but showed no evidence of association with the “1 
miscarriage” and “2 miscarriages” phenotypes.  Collectively, this indicates that for the reported 
associations, at least in the UKBB dataset, the “2 miscarriages” phenotype is more similar to the 
“1 miscarriage” group than the subset of women who have three or more miscarriages and 
justifies the joint analysis of women with 1-2 miscarriages.  
 
 19 
Supplementary Table 1. Associations between the four signals identified in sporadic 
miscarriage and multiple consecutive miscarriage meta-analyses and different miscarriage 
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Given the above, in this paper we aimed to capture the ends of the miscarriage phenotypic 
spectrum and contrast sporadic miscarriage (defined here as 1-2 miscarriages) with very severe 
multiple consecutive miscarriage (3 or more consecutive miscarriages). We have chosen not to 
use the term “recurrent miscarriage” for the latter group, as it might be confusing for readers in 
light of the current definition guidelines, which differ from those used in the past. 
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Supplementary Figure 1. Proportional distribution of a) 
number of pregnancies and b) number of children in 
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Supplementary Figure 2. Manhattan plot (A) and QQ plot 
with 95% confidence interval (B) for sporadic miscarriage 
trans-ethnic meta-analysis (69,054 cases and 359,469) for 
markers present in at least half (n=11) of the cohorts. Genome-
wide significance threshold was set at p-value = 5 × 10-8. 
 C Forest plot of the association signal on chromosome 7 
(rs10270417). Details of association testing in individual cohorts 
can be found in Supplementary Data 2. OR estimates with 95% 


















Supplementary Figure 3. Manhattan (A), and QQ plot 
with 95% confidence interval (B) for sporadic 
miscarriage European ancestry meta-analysis (49,996 
cases and 174,109 controls) filtered for markers 
present in at least half (n=7) of the cohorts. The 
genome-wide significant marker on chromosome 13 
(rs146350366) is highlighted in green on the Manhattan 
plot. Genome-wide significance threshold was set at p-
value = 5 × 10-8. C Forest plot of the association signal 
on chromosome 13 (rs146350366). Details of 
association testing in individual cohorts can be found in 
Supplementary Data 2. Summary effect estimate from 
inverse variance fixed effects meta-analysis. OR 







Supplementary Figure 4. Regional plots for multiple consecutive miscarriage European 
ancestry meta-analysis top hits. A) rs138993181 on chromosome 2; B) rs7859844 on 


















Supplementary Figure 5. ICD codes associated with sporadic (A) and multiple 





ICD10 code observed among the cases. Y-axis is the –log10 P-value of the test of difference 
between the diagnosis frequency among cases and controls. Diagnoses were grouped and 
coloured by the ICD10 chapter. Y-axis is truncated at 10, with diagnosis for which its –log10 
P-value exceeds this value represented by a diamond. Horizontal dash line represents the 
significance threshold after applying the 10% FDR multiple testing correction (5.23×10-3 for 





















Supplementary Figure 6. Two sample Mendelian randomization analysis. Instruments-sporadic 
miscarriage associations (y-axis) against instrument-smoking (a), instrument-alcohol (b), and instrument-

















Supplementary Figure 8. QQ plot for the 17,028 MR-PheWAS results for multiple 
consecutive miscarriage genetic risk score. The three significant outcomes are single items 







Supplementary Figure 9. Forest plot showing endometriosis risk allele effects for multiple 
consecutive miscarriage and pooled effect according to inverse variance weighting and MR-Egger 











Supplementary Figure 10. Hi-C map and Capture Hi-C data visualization for the multiple 
consecutive miscarriage association signal on chromosome 11. The blue vertical line 
represents the location of the signal from GWAS meta-analysis. The 3D Genome Browser31 was 
used for data visualization and ovarian tissue and trophoblast cell data were selected to illustrate 











Supplementary Figure 11. Hi-C map and Capture Hi-C data visualization for multiple 
consecutive miscarriage association signal on chr21. The blue/yellow vertical line represents 
the location of the signal from GWAS meta-analysis. The 3D Genome Browser31 was used for 
data visualization and ovarian tissue and endothelial progenitors were selected to illustrate the 
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